---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-011454"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:27:51.829036+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition Corp. II appoints Albert A. Holman, III to its Board of Directors

## Summary
- Albert A. Holman, III appointed on Feb 8, 2025 as Class III independent director.
- Holman brings life sciences investment banking experience; will serve on Audit Committee.
- Sponsor transferred 30,000 Class B ordinary shares to Holman in connection with appointment.
- Holman executed standard SPAC Letter Agreement and Joinder to Registration Rights Agreement.

## SEC filing metadata
- accession: 0001213900-25-011454
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025011454/0001213900-25-011454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025011454/ea0230467-8k_helixacq2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-011454
- JSON: https://secwatch.observer/filing/0001213900-25-011454.json
- Plain text: https://secwatch.observer/filing/0001213900-25-011454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.